ICAgen Inc. trades in the stock market as ticker ICGN. Business Summary & Profile For ICAgen Inc..

ICAgen Inc.

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc. The company was founded in 1992 and is based in Dur...
Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

inca minerals ltd-new shares (ICGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
ICGN:AU Advanced Stock Chart

Related News

No related news articles were found.

inca minerals ltd-new shares (ICGN) Related News

No Related News Found

inca minerals ltd-new shares (ICGN) Key Developments

Inca Minerals Limited Announces Executive Changes

Inca Minerals Limited announced that during the period 3 July 2015 to 19 July 2015 Inca’s Company Secretary, Mr. Justin Walawski, will be in North America. During the aforementioned period the company has appointed Mr. Rowan Caren to act as Joint Company Secretary. Mr. Caren’s appointment as Joint Company Secretary formally commences 2 July 2015 and ends 20 July 2015.

Inca Minerals Announces Address Change of Registered Office

Inca Minerals Limited announced that it has changed its registered office and registered place of business to the following: Suite 1, 16 Nicholson Road, Subiaco, Western Australia 6008.

Inca Minerals Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Inca Minerals Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue of AUD 18,469 compared to AUD 48,430 a year ago. Loss before income tax was AUD 664,177 compared to AUD 1,184,583 a year ago. Loss attributable to the members of the company was AUD 664,177 or 0.11 cent per basic and diluted share compared to AUD 1,184,583 or 0.28 cent per basic and diluted share a year ago. Net cash used in operating activities was AUD 444,337 compared to AUD 446,712 a year ago. Payments for property, plant and equipment were AUD 1,053 compared to AUD 46,383 a year ago. Payments for exploration and evaluation expenditures were AUD 1,330,198 compared to AUD 1,561,470 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICGN:AU A$0.00 AUD 0.00

ICGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICGN.

Industry Analysis


Industry Average

Valuation ICGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 316.5x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 377.5x

Sponsored Financial Commentaries

Sponsored Links

This Rosslyn-based company is uprooting itself after a quarter-century
UMd. Athletic Department red ink nearly tripled in fiscal 2014

Write Comment Create Account
The information contained herein does not suggest or imply and should not be construed, in any manner, a guarantee of future performance and/or investment advice.www.nasdaqstockranking.com is not a registered financial advisor or otherwise qualified as investment professional. The content posted here are only the opinion of the poster and should not be taken as recommendations to buy or sell any security or financial instrument. Trading and investing inherently involves the risk of significant loss of money, and can involve the risk of loss of more than the amount invested. Before executing any trade readers are strongly cautioned to consult with a financial adviser of their choosing. www.nasdaqstockranking.com, its affiliates and partners, shall have no liability for investment or other decisions based upon any Content and/or decisions based upon our syndicated page content.
@2012 www.nasdaqstockranking.com - info {at} www.nasdaqstockranking.comContactUs